Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Hyperlipoproteinemias

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 15 articles: HTML format

Single Articles

November 2025
1. LAFFIN LJ, Nicholls SJ, Scott RS, Clifton PM, et al
   Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3.
   N Engl J Med. 2025;393:2119-2130.
   PubMed     Abstract available
   
   
   
2. MARSTON NA, Bergmark BA, Alexander VJ, Prohaska TA, et al
   Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.
   N Engl J Med. 2025 Nov 8. doi: 10.1056/NEJMoa2512761.
   PubMed     Abstract available
   
   
   August 2025
3. BERGMARK BA, Marston NA, Prohaska TA, Alexander VJ, et al
   Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia.
   N Engl J Med. 2025 Aug 30. doi: 10.1056/NEJMoa2507227.
   PubMed     Abstract available
   
   
   July 2025
4. MCFARLAND R, Hyslop LA, Feeney C, Pillai RN, et al
   Mitochondrial Donation in a Reproductive Care Pathway for mtDNA Disease.
   N Engl J Med. 2025;393:461-468.
   PubMed     Abstract available
   
   
   May 2025
5. NICHOLLS SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, et al
   Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.
   N Engl J Med. 2025 May 7. doi: 10.1056/NEJMoa2415820.
   PubMed     Abstract available
   
   
   March 2025
6. MAGNUSSEN C, Alegre-Diaz J, Al-Nasser LA, Amouyel P, et al
   Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
   N Engl J Med. 2025 Mar 30. doi: 10.1056/NEJMoa2415879.
   PubMed     Abstract available
   
   
   September 2024
7. WATTS GF, Rosenson RS, Hegele RA, Goldberg IJ, et al
   Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk.
   N Engl J Med. 2024 Sep 2. doi: 10.1056/NEJMoa2409368.
   PubMed     Abstract available
   
   
   August 2024
8. FABBRINI E, Rady B, Koshkina A, Jeon JY, et al
   Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD.
   N Engl J Med. 2024;391:475-476.
   PubMed    
   
   
   May 2024
9. ROSENSON RS, Gaudet D, Hegele RA, Ballantyne CM, et al
   Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.
   N Engl J Med. 2024 May 29. doi: 10.1056/NEJMoa2404147.
   PubMed     Abstract available
   
   
   
10. BALLANTYNE CM, Vasas S, Azizad M, Clifton P, et al
    Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.
    N Engl J Med. 2024 May 28. doi: 10.1056/NEJMoa2404143.
    PubMed     Abstract available
    
    
    April 2024
11. BERGMARK BA, Marston NA, Prohaska TA, Alexander VJ, et al
    Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
    N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2402309.
    PubMed     Abstract available
    
    
    
12. WATTS GF
    Shooting the Messenger to Treat Hypertriglyceridemia.
    N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMe2402653.
    PubMed    
    
    
    
13. STROES ESG, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, et al
    Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome.
    N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2400201.
    PubMed     Abstract available
    
    
    February 2024
14. ALEXANDER VJ, Karwatowska-Prokopczuk E, Prohaska TA, Li L, et al
    Volanesorsen to Prevent Acute Pancreatitis in Hypertriglyceridemia.
    N Engl J Med. 2024;390:476-477.
    PubMed    
    
    
    April 2023
15. ALEXANDER JH
    Benefits of Bempedoic Acid - Clearer Now.
    N Engl J Med. 2023;388:1425-1426.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hyperlipoproteinemias is free of charge.